Switching SGLT2 Inhibitors: Generic Transitions and Continuity of Care

In "Switching SGLT2 Inhibitors: Generic Transitions and Continuity of Care," Dr. Vaduganathan considers what happens clinically when a patient switches between SGLT2 inhibitors, including to a generic.

Dr. Vaduganathan addresses a question that comes up often in practice: what happens clinically when a patient stabilized on one SGLT2 inhibitor is switched to another, whether for formulary reasons or because a generic option becomes available. He explains that because SGLT2 inhibitors are broadly well tolerated as a class, switching within the class has generally not caused problems. Clinicians have not seen new, drug-specific side effects emerge when patients move from one agent to another, which he attributes to the therapies sharing a common mechanism and a similar overall safety profile.

When the switch is specifically to a generic formulation, Dr. Vaduganathan says the natural question is bioequivalence with the branded product. Once that bioequivalence can be assured, he generally has no concerns about moving patients from branded to generic therapy. He adds that the switch often improves a patient's overall financial burden and can ease broader concerns about financial toxicity in patients managing multiple medications at once, since a lower-cost generic frees up resources elsewhere in the regimen.

His one consistent concern, he says, is not the switch itself but any gap in therapy that the switch creates. Even a short interruption while a prescription transitions between agents exposes patients to excess cardiovascular and kidney risk, since the protective effect of SGLT2 inhibitors depends on continuous use. Dr. Vaduganathan says he tries to minimize any such gap wherever possible, coordinating prescriptions and refills so that a formulary-driven or generic-driven switch does not translate into missed doses. He frames continuity, not the specific agent, as the priority whenever patients change therapies within the class.

Our next episode, "SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Heart Failure," broadens the lens to compare SGLT2 inhibitors with GLP-1 receptor agonists across their respective indications.